WallStSmart

S&P Global Inc (SPGI)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

S&P Global Inc generates 399% more annual revenue ($15.34B vs $3.07B). SPGI leads profitability with a 29.1% profit margin vs 16.1%. SPGI appears more attractively valued with a PEG of 1.50. SPGI earns a higher WallStSmart Score of 67/100 (B-).

SPGI

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.97

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SPGIUndervalued (+40.5%)

Margin of Safety

+40.5%

Fair Value

$687.02

Current Price

$408.48

$278.54 discount

UndervaluedFair: $687.02Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SPGI5 strengths · Avg: 8.8/10
Operating MarginProfitability
38.3%10/10

Strong operational efficiency at 38.3%

Market CapQuality
$124.51B9/10

Large-cap with strong market position

Profit MarginProfitability
29.1%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
32.0%8/10

Earnings expanding 32.0% YoY

Free Cash FlowQuality
$1.70B8/10

Generating 1.7B in free cash flow

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

SPGI2 concerns · Avg: 4.0/10
P/E RatioValuation
28.0x4/10

Moderate valuation

Altman Z-ScoreHealth
1.974/10

Grey zone — moderate risk

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : SPGI

The strongest argument for SPGI centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 29.1% and operating margin at 38.3%.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : SPGI

The primary concerns for SPGI are P/E Ratio, Altman Z-Score.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

SPGI carries more volatility with a beta of 1.22 — expect wider price swings.

SPGI is growing revenue faster at 9.0% — sustainability is the question.

SPGI generates stronger free cash flow (1.7B), providing more financial flexibility.

Monitor FINANCIAL DATA & STOCK EXCHANGES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SPGI scores higher overall (67/100 vs 55/100), backed by strong 29.1% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

S&P Global Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

S&P Global Inc. is an American publicly traded corporation headquartered in Manhattan, New York City. Its primary areas of business are financial information and analytics.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?